Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APX-343A Monotherapy and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT07123415Phase 1Recruiting
- Sponsor
- AptaBio Therapeutics Inc.
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- Prophylactic Vaccines, Small Molecules, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of APX-343A in solid tumor (advanced stage) (2 arms), sponsored by AptaBio Therapeutics Inc. Primary endpoints: Safety and Tolerability, Maximum Tolerated Dose and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
APX-343A
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07123415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07123415.